Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sutro Biopharma, Inc. (STRO)
USD26.23
+0.20 (+0.77%)
US NASDAQ Healthcare Biotechnology
Address
111 Oyster Point Boulevard 94080
South San Francisco, CA, US
South San Francisco, CA, US
CEO
Jane Chung
Website
sutrobio.com
IPO
2018-09-27
CIK 1382101 ISIN US8693672011
Description
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD26.23
+0.20 (+0.77%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
324.4K
Beta
1.55
Float Shares
6.00M
Free Float %
70.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.98% | -3.73% | +33.50% | +137.75% | +324.53% | +232.07% | +424.15% | -34.66% | -80.48% | -74.72% | -74.72% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (19 ratings, all time)
Buy
Price Targets & DCF
Current price
26.23
Low
50.00
+90.6%
Consensus
50.00
+90.6%
Median
50.00
+90.6%
High
50.00
+90.6%
Ratings Trend (MoM)
85% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 9 | +1 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
50.00
+90.6%
|
| Last Quarter | 1 |
50.00
+90.6%
|
| Last Year | 1 |
50.00
+90.6%
|
| All Time | 13 |
124.62
+375.1%
|
Quality scores
Altman Z-Score
-5.60
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+65.2% ★ Q1'26: -16.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+24.0% Q1'26: +67.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-183.3% Q1'26: -291.1% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-102.4% Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+10.6% Q1'26: +57.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.16× Q1'26: -0.11× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 10 Rev. Ana. 7 EPS Ana. |
Dec 2027 8 Rev. Ana. 7 EPS Ana. |
Dec 2028 7 Rev. Ana. 7 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 6 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
38.42M
est: 25.36M (+51.5%)
|
42.74M
est: 41.38M (+3.3%)
|
42.72M
est: 42.67M (+0.1%)
|
61.88M
est: 62.36M (-0.8%)
|
67.77M
est: 68.38M (-0.9%)
|
153.73M
est: 154.07M (-0.2%)
|
62.04M
est: 59.04M (+5.1%)
|
102.48M
est: 99.18M (+3.3%)
|
32.87M
11.95M – 71.71M
-66.9% YoY
|
23.10M
4.31M – 41.87M
-29.7% YoY
|
38.24M
12.01M – 79.47M
+65.5% YoY
|
55.00M
17.27M – 114.30M
+43.8% YoY
|
70.89M
22.26M – 147.33M
+28.9% YoY
|
| EBITDA |
-32.82M
est: -20.28M (-61.8%)
|
-46.62M
est: -33.08M (-40.9%)
|
-23.75M
est: -34.11M (+30.4%)
|
-97.56M
est: -90.06M (-8.3%)
|
-105.07M
est: -104.35M (-0.7%)
|
-67.92M
est: -135.40M (+49.8%)
|
-180.45M
est: -51.89M (-247.7%)
|
-97.63M
est: -87.16M (-12.0%)
|
-28.89M
-63.03M – -10.50M
+66.9% YoY
|
-20.30M
-36.80M – -3.79M
+29.7% YoY
|
-33.61M
-69.84M – -10.55M
-65.5% YoY
|
-48.34M
-100.46M – -15.18M
-43.8% YoY
|
-62.31M
-129.49M – -19.56M
-28.9% YoY
|
| EBIT |
-37.22M
est: -21.01M (-77.1%)
|
-51.39M
est: -34.28M (-49.9%)
|
-28.05M
est: -35.35M (+20.7%)
|
-102.40M
est: -94.63M (-8.2%)
|
-113.36M
est: -119.46M (+5.1%)
|
-74.73M
est: -138.23M (+45.9%)
|
-187.67M
est: -52.97M (-254.3%)
|
-104.95M
est: -88.98M (-17.9%)
|
-29.49M
-64.34M – -10.72M
+66.9% YoY
|
-20.73M
-37.57M – -3.87M
+29.7% YoY
|
-34.31M
-71.30M – -10.77M
-65.5% YoY
|
-49.35M
-102.56M – -15.49M
-43.8% YoY
|
-63.61M
-132.19M – -19.97M
-28.9% YoY
|
| Net Income |
-35.32M
est: -412.19M (+91.4%)
|
-55.74M
est: -190.74M (+70.8%)
|
-32.13M
est: 6.34M (-606.9%)
|
-105.54M
est: -97.97M (-7.7%)
|
-119.20M
est: -112.81M (-5.7%)
|
-106.79M
est: -16.41M (-550.8%)
|
-227.46M
est: -245.22M (+7.2%)
|
-191.09M
est: -148.17M (-29.0%)
|
-87.64M
-132.77M – -42.51M
+40.8% YoY
|
-77.87M
-117.35M – -38.39M
+11.2% YoY
|
-73.10M
-107.31M – -38.89M
+6.1% YoY
|
-62.76M
-150.73M – -6.79M
+14.1% YoY
|
-57.89M
-139.04M – -6.26M
+7.8% YoY
|
| SGA |
21.38M
est: 19.44M (+10.0%)
|
32.59M
est: 31.72M (+2.7%)
|
36.82M
est: 32.71M (+12.5%)
|
56.00M
est: 58.24M (-3.8%)
|
59.54M
est: 64.00M (-7.0%)
|
62.58M
est: 103.90M (-39.8%)
|
48.45M
est: 39.82M (+21.7%)
|
41.02M
est: 66.88M (-38.7%)
|
22.17M
8.06M – 48.36M
-66.9% YoY
|
15.58M
2.91M – 28.24M
-29.7% YoY
|
25.79M
8.10M – 53.59M
+65.5% YoY
|
37.09M
11.65M – 77.08M
+43.8% YoY
|
47.81M
15.01M – 99.36M
+28.9% YoY
|
| EPS |
-15.50
est: -53.65 (+71.1%)
|
-24.30
est: -24.83 (+2.1%)
|
-9.90
est: 0.83 (-1,300.0%)
|
-22.90
est: -22.33 (-2.6%)
|
-23.50
est: -25.11 (+6.4%)
|
-17.80
est: -1.89 (-842.2%)
|
-29.60
est: -28.98 (-2.1%)
|
-22.49
est: -17.81 (-26.3%)
|
-8.97
-15.62 – -5.00
+49.6% YoY
|
-7.85
-13.81 – -4.52
+12.6% YoY
|
-7.88
-12.63 – -4.58
-0.4% YoY
|
-7.39
-17.74 – -0.80
+6.3% YoY
|
-6.81
-16.36 – -0.74
+7.8% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-23 | Citizens | Market Outperform | Market Outperform | Maintain |
| 2026-04-17 | Citizens | Market Outperform | Market Outperform | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-138.00M
OE per share TTM
-14.43
Owner's Yield
-41.84%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
42.6%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
14
Total invested
32.14M
Insider transactions (90d)
0
Beneficial owners (>5%)
35
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Steven A. Cohen | 5.93M | 7.90% | — | 5.93M | — | — | IN | Delaware | 2024-04-05 | ↗ |
| 2 | Point72 Asset Management, L.P. | 5.79M | 7.70% | — | 5.79M | — | — | PN | Delaware | 2024-04-05 | ↗ |
| 3 | Point72 Capital Advisors, Inc. | 5.79M | 7.70% | — | 5.79M | — | — | CO | Delaware | 2024-04-05 | ↗ |
| 4 | (1) BlackRock, Inc. | 3.70M | 8.00% | 3.56M | — | 3.70M | — | HC | Delaware | 2022-02-03 | ↗ |
| 5 | Adage Capital Management, L.P. | 3.55M | 5.86% | — | 3.55M | — | — | IA, PN | Delaware | 2023-10-10 | ↗ |
| 6 | Adage Capital Partners GP, L.L.C. | 3.55M | 5.86% | — | 3.55M | — | — | OO | Delaware | 2023-10-10 | ↗ |
| 7 | Adage Capital Partners, L.P. | 3.55M | 5.86% | — | 3.55M | — | — | PN | Delaware | 2023-10-10 | ↗ |
| 8 | Phillip Gross | 3.55M | 5.86% | — | 3.55M | — | — | IN | Delaware | 2023-10-10 | ↗ |
| 9 | Robert Atchinson | 3.55M | 5.86% | — | 3.55M | — | — | IN | Delaware | 2023-10-10 | ↗ |
| 10 | Israel A. Englander | 3.45M | 5.70% | — | 3.45M | — | 3.45M | IN | Delaware | 2024-01-17 | ↗ |
| 11 | Millennium Group Management LLC | 3.45M | 5.70% | — | 3.45M | — | 3.45M | OO | Delaware | 2024-01-17 | ↗ |
| 12 | Millennium Management LLC | 3.45M | 5.70% | — | 3.45M | — | 3.45M | OO | Delaware | 2024-01-17 | ↗ |
| 13 | David Rosen | 3.21M | 5.59% | — | 3.21M | — | — | IN | United States of America | 2023-02-10 | ↗ |
| 14 | LP | 3.21M | 5.59% | — | 3.21M | — | — | IA, PN | State of Delaware | 2023-02-10 | ↗ |
| 15 | BVF Inc. | 3.16M | 6.80% | — | — | — | 3.16M | CO | Delaware | 2022-01-18 | ↗ |
| 16 | BVF Partners L.P. | 3.16M | 6.80% | — | — | — | 3.16M | IA, PN | Delaware | 2022-01-18 | ↗ |
| 17 | Mark N. Lampert | 3.16M | 6.80% | — | — | — | 3.16M | IN | Delaware | 2022-01-18 | ↗ |
| 18 | Integrated Core Strategies (US) LLC | 3.11M | 5.10% | — | 3.11M | — | 3.11M | OO | Delaware | 2024-01-17 | ↗ |
| 19 | BVF GP HOLDINGS LLC | 2.95M | 6.40% | — | — | — | 2.95M | OO | Delaware | 2022-01-18 | ↗ |
| 20 | Eventide Asset Management, LLC | 2.71M | 5.90% | 2.71M | — | 2.71M | — | IA | Delaware | 2022-02-14 | ↗ |
| 21 | Aaron Cowen | 2.47M | 5.40% | — | 2.47M | — | 2.47M | HC, IN | — | 2022-02-11 | ↗ |
| 22 | Averill Master Fund, Ltd. | 2.47M | 5.40% | — | 2.47M | — | 2.47M | CO | — | 2022-02-11 | ↗ |
| 23 | Suvretta Capital Management, LLC | 2.47M | 5.40% | — | 2.47M | — | 2.47M | IA, OO | — | 2022-02-11 | ↗ |
| 24 | BRISTOL-MYERS SQUIBB COMPANY 22-0790350 | 1.73M | 3.80% | — | 1.73M | — | 1.73M | CO | Delaware, U.S.A. | 2021-04-05 | ↗ |
| 25 | CELGENE CORPORATION 22-2711928 | 1.73M | 3.80% | — | 1.73M | — | 1.73M | CO | Delaware, U.S.A. | 2021-04-05 | ↗ |
| 26 | BVF I GP LLC | 1.71M | 3.70% | — | — | — | 1.71M | OO | Delaware | 2022-01-18 | ↗ |
| 27 | Biotechnology Value Fund, L.P. | 1.71M | 3.70% | — | — | — | 1.71M | PN | Delaware | 2022-01-18 | ↗ |
| 28 | BVF II GP LLC | 1.24M | 2.70% | — | — | — | 1.24M | OO | Delaware | 2022-01-18 | ↗ |
| 29 | Biotechnology Value Fund II, L.P. | 1.24M | 2.70% | — | — | — | 1.24M | PN | Delaware | 2022-01-18 | ↗ |
| 30 | 66-0677421 | 1.14M | 2.50% | — | 1.14M | — | — | OO | Delaware | 2021-02-16 | ↗ |
| 31 | 72-1614961 | 1.14M | 2.50% | — | 1.14M | — | — | OO | Delaware | 2021-02-16 | ↗ |
| 32 | Ridgeback Capital Management LLC 42-1684320 | 1.14M | 2.50% | — | 1.14M | — | — | OO | Delaware | 2021-02-16 | ↗ |
| 33 | BVF Partners OS Ltd. | 156.7K | 1.00% | — | — | — | 156.7K | CO | Delaware | 2022-01-18 | ↗ |
| 34 | Biotechnology Value Trading Fund OS LP | 156.7K | 1.00% | — | — | — | 156.7K | PN | Delaware | 2022-01-18 | ↗ |
| 35 | Cubist Systematic Strategies, LLC | 141.4K | 0.20% | — | 141.4K | — | — | OO | Delaware | 2024-04-05 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
14
-46 vs prev Q
New positions
6
Closed positions
52
Increased
7
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 75.6K +75.6K (+100.0%) | 874.62M +874.6M (+100.0%) | 0.89% +0.891 pp | 0.29% +0.289 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 2 | AFFINITY ASSET ADVISORS, LLC | 748.4K +748.4K (+100.0%) | 8.66M +8.7M (+100.0%) | 8.82% +8.818 pp | 0.49% +0.493 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 3 | KYNAM CAPITAL MANAGEMENT, LP | 479.6K +479.6K (+100.0%) | 5.55M +5.5M (+100.0%) | 5.65% +5.651 pp | 0.35% +0.355 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 4 | MILLENNIUM MANAGEMENT LLC | 418.2K +418.2K (+100.0%) | 4.84M +4.8M (+100.0%) | 4.93% +4.928 pp | 0.00% +0.002 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 5 | VANGUARD GROUP INC | 375.8K +375.8K (+100.0%) | 4.35M +4.3M (+100.0%) | 4.43% +4.428 pp | 0.00% +0.000 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 6 | ACADIAN ASSET MANAGEMENT LLC | 338.0K +338.0K (+100.0%) | 3.91M +3.9M (+100.0%) | 3.98% +3.982 pp | 0.01% +0.006 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 7 | VELAN CAPITAL INVESTMENT MANAGEMENT LP | 312.0K +312.0K (+100.0%) | 3.61M +3.6M (+100.0%) | 3.68% +3.676 pp | 2.09% +2.094 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 8 | MERCK & CO., INC. | 272.4K -2.5M (-90.0%) | 3.15M +786.0K (+33.2%) | 3.21% -10.634 pp | 1.14% +0.103 pp | USD98.35 -88.2% | 5 qtrs — |
| 9 | VESTAL POINT CAPITAL, LP | 243.0K +243.0K (+100.0%) | 2.81M +2.8M (+100.0%) | 2.86% +2.863 pp | 0.10% +0.096 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 10 | BALYASNY ASSET MANAGEMENT L.P. | 230.0K +230.0K (+100.0%) | 2.66M +2.7M (+100.0%) | 2.71% +2.711 pp | 0.00% +0.003 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 11 | SAMSARA BIOCAPITAL, LLC | 204.5K +204.5K (+100.0%) | 2.37M +2.4M (+100.0%) | 2.41% +2.410 pp | 0.24% +0.244 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 12 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 200.0K +200.0K (+100.0%) | 2.31M +2.3M (+100.0%) | 2.36% +2.357 pp | 0.00% +0.004 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 13 | EVERSEPT PARTNERS, LP | 193.6K +193.6K (+100.0%) | 2.24M +2.2M (+100.0%) | 2.28% +2.281 pp | 0.11% +0.113 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 14 | OPALEYE MANAGEMENT INC. | 190.7K +190.7K (+100.0%) | 2.21M +2.2M (+100.0%) | 2.25% +2.247 pp | 0.29% +0.291 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 15 | POINT72 ASSET MANAGEMENT, L.P. | 179.1K +179.1K (+100.0%) | 2.07M +2.1M (+100.0%) | 2.11% +2.110 pp | 0.00% +0.002 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 16 | TANG CAPITAL MANAGEMENT LLC | 139.6K +139.6K (+100.0%) | 1.62M +1.6M (+100.0%) | 1.65% +1.645 pp | 0.08% +0.080 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 17 | RENAISSANCE TECHNOLOGIES LLC | 122.9K +122.9K (+100.0%) | 1.42M +1.4M (+100.0%) | 1.45% +1.448 pp | 0.00% +0.002 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 18 | BLACKROCK, INC. | 117.4K +117.4K (+100.0%) | 1.36M +1.4M (+100.0%) | 1.38% +1.384 pp | 0.00% +0.000 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 19 | GSA CAPITAL PARTNERS LLP | 89.1K +89.1K (+100.0%) | 1.03M +1.0M (+100.0%) | 1.05% +1.050 pp | 0.09% +0.089 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 20 | MARSHALL WACE, LLP | 85.6K +85.6K (+100.0%) | 990.6K +990.6K (+100.0%) | 1.01% +1.009 pp | 0.00% +0.001 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 21 | GEODE CAPITAL MANAGEMENT, LLC | 84.0K +84.0K (+100.0%) | 972.0K +972.0K (+100.0%) | 0.99% +0.990 pp | 0.00% +0.000 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 22 | ACUTA CAPITAL PARTNERS, LLC | 67.5K +67.5K (+100.0%) | 780.4K +780.4K (+100.0%) | 0.79% +0.795 pp | 0.53% +0.530 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 23 | ADAR1 CAPITAL MANAGEMENT, LLC | 67.1K +67.1K (+100.0%) | 776.1K +776.1K (+100.0%) | 0.79% +0.790 pp | 0.06% +0.057 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 24 | TWO SIGMA INVESTMENTS, LP | 46.5K +46.5K (+100.0%) | 537.9K +537.9K (+100.0%) | 0.55% +0.548 pp | 0.00% +0.001 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 25 | FISHER ASSET MANAGEMENT, LLC | 35.3K +35.3K (+100.0%) | 408.5K +408.5K (+100.0%) | 0.42% +0.416 pp | 0.00% +0.000 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 26 | STATE STREET CORP | 34.3K +34.3K (+100.0%) | 396.5K +396.5K (+100.0%) | 0.40% +0.404 pp | 0.00% +0.000 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 27 | CITADEL ADVISORS LLC | 32.1K +32.1K (+100.0%) | 371.2K +371.2K (+100.0%) | 0.38% +0.378 pp | 0.00% +0.000 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 28 | SHAY CAPITAL LLC | 24.3K +24.3K (+100.0%) | 280.6K +280.6K (+100.0%) | 0.29% +0.286 pp | 0.03% +0.029 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 29 | JANE STREET GROUP, LLC | 22.9K +22.9K (+100.0%) | 265.5K +265.5K (+100.0%) | 0.27% +0.270 pp | 0.00% +0.000 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 30 | AQR CAPITAL MANAGEMENT LLC | 18.0K +18.0K (+100.0%) | 208.7K +208.7K (+100.0%) | 0.21% +0.213 pp | 0.00% +0.000 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 31 | TWO SIGMA ADVISERS, LP | 17.6K +17.6K (+100.0%) | 203.4K +203.4K (+100.0%) | 0.21% +0.207 pp | 0.00% +0.000 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 32 | AJU IB INVESTMENT CO., LTD. | 17.5K -157.5K (-90.0%) | 202.5K +49.4K (+32.2%) | 0.21% -0.683 pp | 0.89% +0.756 pp | USD98.35 -88.2% | 5 qtrs — |
| 33 | INVESCO LTD. | 17.0K +17.0K (+100.0%) | 196.3K +196.3K (+100.0%) | 0.20% +0.200 pp | 0.00% +0.000 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 34 | MORGAN STANLEY | 15.9K +15.9K (+100.0%) | 184.2K +184.2K (+100.0%) | 0.19% +0.188 pp | 0.00% +0.000 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 35 | GOLDMAN SACHS GROUP INC | 15.7K +15.7K (+100.0%) | 181.3K +181.3K (+100.0%) | 0.18% +0.185 pp | 0.00% +0.000 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 36 | RBF CAPITAL, LLC | 15.3K +15.3K (+100.0%) | 176.7K +176.7K (+100.0%) | 0.18% +0.180 pp | 0.01% +0.008 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 37 | NORTHERN TRUST CORP | 14.4K +14.4K (+100.0%) | 166.4K +166.4K (+100.0%) | 0.17% +0.169 pp | 0.00% +0.000 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 38 | OMERS ADMINISTRATION CORP | 11.0K +11.0K (+100.0%) | 127.5K +127.5K (+100.0%) | 0.13% +0.130 pp | 0.00% +0.001 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 39 | STATE OF TENNESSEE, TREASURY DEPARTMENT | 7.4K +7.4K (+100.0%) | 110.6K +110.6K (+100.0%) | 0.09% +0.087 pp | 0.00% +0.000 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 40 | UBS GROUP AG | 7.9K +7.9K (+100.0%) | 91.1K +91.1K (+100.0%) | 0.09% +0.093 pp | 0.00% +0.000 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 41 | BANK OF AMERICA CORP /DE/ | 4.2K +4.2K (+100.0%) | 48.7K +48.7K (+100.0%) | 0.05% +0.050 pp | 0.00% +0.000 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 42 | CWM, LLC | 1.5K +1.5K (+100.0%) | 17.0K +17.0K (+100.0%) | 0.02% +0.018 pp | 0.00% +0.000 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 43 | ADVISOR GROUP HOLDINGS, INC. | 1.3K +1.3K (+100.0%) | 15.5K +15.5K (+100.0%) | 0.02% +0.016 pp | 0.00% +0.000 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 44 | FMR LLC | 1.1K +1.1K (+100.0%) | 12.8K +12.8K (+100.0%) | 0.01% +0.013 pp | 0.00% +0.000 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 45 | CITIGROUP INC | 1.0K +1.0K (+100.0%) | 12.1K +12.1K (+100.0%) | 0.01% +0.012 pp | 0.00% +0.000 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 46 | FNY INVESTMENT ADVISERS, LLC | 1.0K +1.0K (+100.0%) | 11.0K +11.0K (+100.0%) | 0.01% +0.012 pp | 0.00% +0.003 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 47 | JPMORGAN CHASE & CO | 741.00 +741.0 (+100.0%) | 8.6K +8.6K (+100.0%) | 0.01% +0.009 pp | 0.00% +0.000 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 48 | PHYSICIAN WEALTH ADVISORS, INC. | 182.00 +182.0 (+100.0%) | 2.1K +2.1K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 49 | BNP PARIBAS ARBITRAGE, SNC | 111.00 +111.0 (+100.0%) | 1.3K +1.3K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 50 | WELLS FARGO & COMPANY/MN | 100.00 +100.0 (+100.0%) | 1.2K +1.2K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 51 | PNC FINANCIAL SERVICES GROUP, INC. | 62.00 +62.0 (+100.0%) | 717.00 +717.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD11.56 +0.1% | 1 qtrs NEW |
| 52 | FORTITUDE FAMILY OFFICE, LLC | 56.00 +56.0 (+100.0%) | 648.00 +648.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD11.55 +0.2% | 1 qtrs NEW |
| 53 | BOGART WEALTH, LLC | 50.00 -450.0 (-90.0%) | 579.00 +145.0 (+33.4%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD199.84 -94.2% | 12 qtrs — |
| 54 | PARALLEL ADVISORS, LLC | 47.00 -418.0 (-89.9%) | 544.00 +140.0 (+34.7%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD199.68 -94.2% | 20 qtrs — |
| 55 | NISA INVESTMENT ADVISORS, LLC | 44.00 +44.0 (+100.0%) | 509.00 +509.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 56 | EVERSOURCE WEALTH ADVISORS, LLC | 31.00 -423.0 (-93.2%) | 359.00 -35.0 (-8.9%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD96.87 -88.1% | 5 qtrs — |
| 57 | HIGHMARK WEALTH MANAGEMENT LLC | 23.00 +23.0 (+100.0%) | 266.00 +266.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD11.57 +0.0% | 1 qtrs NEW |
| 58 | COMERICA BANK | 3.00 +3.0 (+100.0%) | 35.00 +35.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD11.33 +2.1% | 1 qtrs NEW |
| 59 | SRS CAPITAL ADVISORS, INC. | 3.00 +3.0 (+100.0%) | 35.00 +35.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD11.33 +2.1% | 1 qtrs NEW |
| 60 | GROUP ONE TRADING, L.P. | 2.00 +2.0 (+100.0%) | 23.00 +23.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD11.50 +0.6% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 53 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.51% | 111.6K | 0.20% |
| 2 | Invesco Russell 2000 Dynamic Multifactor ETF OMFS | 0.30% | 854.3K | 0.39% |
| 3 | iShares Micro-Cap ETF IWC | 0.11% | 1.59M | 0.60% |
| 4 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.05% | 589.0K | 0.40% |
| 5 | iShares Ageing Population UCITS ETF AGED.L | 0.04% | 351.3K | 0.40% |
| 6 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.03% | 359.8K | 0.20% |
| 7 | iShares Russell 2000 Value ETF IWN | 0.03% | 3.60M | 0.24% |
| 8 | Invesco RAFI US 1500 Small-Mid ETF PRFZ | 0.02% | 490.8K | 0.34% |
| 9 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.02% | 482.9K | 0.30% |
| 10 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.02% | 48.2K | 0.25% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
3.00
Bullish
Buys
18
Sells
18
Shares acquired
362.9K
Shares disposed
27.8K
Cash buys
—
Cash sales
—
Net activity
+335,037
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | Pauling David | Officer | M-Exempt | A | Common Stock | 675 | 0.00 | — | 10,025 | D | ↗ |
| 2026-03-04 | Chung Jane | Director / Officer | M-Exempt | A | Common Stock | 788 | 0.00 | — | 21,567 | D | ↗ |
| 2026-03-02 | Pauling David | Officer | M-Exempt | A | Common Stock | 2,356 | 0.00 | — | 10,320 | D | ↗ |
| 2026-03-02 | Gerber Hans-Peter | Officer | F-InKind | D | Common Stock | 1,170 | 20.55 | 24.0K | 9,518 | D | ↗ |
| 2026-03-02 | Chung Jane | Director / Officer | M-Exempt | D | Restricted Stock Units (RSUs) | 7,750 | 0.00 | — | 23,250 | D | ↗ |
| 2026-03-02 | Chow Gregory K. | Officer | A-Award | A | Restricted Stock Units (RSUs) | 5,000 | 0.00 | — | 5,000 | D | ↗ |
| 2026-03-01 | Pauling David | Officer | M-Exempt | D | Restricted Stock Units (RSUs) | 842 | 0.00 | — | 1,686 | D | ↗ |
| 2026-03-01 | Gerber Hans-Peter | Officer | M-Exempt | D | Restricted Stock Units (RSUs) | 1,125 | 0.00 | — | 2,250 | D | ↗ |
| 2026-03-01 | Chung Jane | Director / Officer | M-Exempt | D | Restricted Stock Units (RSUs) | 688 | 0.00 | — | 688 | D | ↗ |
| 2025-12-23 | Wigginton Jon Marc | Director | A-Award | A | Stock Option (right to buy) | 1,500 | 10.38 | 15.6K | 1,500 | D | ↗ |
| 2025-12-23 | Petree Daniel H | Director | A-Award | A | Stock Option (right to buy) | 1,500 | 10.38 | 15.6K | 1,500 | D | ↗ |
| 2025-12-23 | Pauling David | Officer | A-Award | A | Stock Option (right to buy) | 7,200 | 10.38 | 74.7K | 7,200 | D | ↗ |
| 2025-12-23 | PANEK JAMES P | Director | A-Award | A | Stock Option (right to buy) | 1,500 | 10.38 | 15.6K | 1,500 | D | ↗ |
| 2025-12-23 | MATSUI CONNIE | Director | A-Award | A | Stock Option (right to buy) | 1,500 | 10.38 | 15.6K | 1,500 | D | ↗ |
| 2025-12-23 | Lobacki Joseph M | Director | A-Award | A | Stock Option (right to buy) | 1,500 | 10.38 | 15.6K | 1,500 | D | ↗ |
| 2025-12-23 | Jagpal Sukhi | Director | A-Award | A | Stock Option (right to buy) | 1,500 | 10.38 | 15.6K | 1,500 | D | ↗ |
| 2025-12-23 | Hunter Heidi | Director | A-Award | A | Stock Option (right to buy) | 1,500 | 10.38 | 15.6K | 1,500 | D | ↗ |
| 2025-12-23 | Gerber Hans-Peter | Officer | A-Award | A | Stock Option (right to buy) | 7,925 | 10.38 | 82.3K | 7,925 | D | ↗ |
| 2025-12-23 | Dybbs Michael | Director | A-Award | A | Stock Option (right to buy) | 1,500 | 10.38 | 15.6K | 1,500 | D | ↗ |
| 2025-12-23 | Chow Gregory K. | Officer | A-Award | A | Stock Option (right to buy) | 8,200 | 10.38 | 85.1K | 8,200 | D | ↗ |
| 2025-12-12 | Chung Jane | Director / Officer | M-Exempt | A | Common Stock | 2,500 | 0.00 | — | 14,785 | D | ↗ |
| 2025-10-15 | Pauling David | Officer | P-Purchase | A | Common Stock | 12,504 | 0.80 | 10.0K | 71,737 | D | ↗ |
| 2025-10-15 | MATSUI CONNIE | Director | P-Purchase | A | Common Stock | 50,000 | 0.80 | 40.0K | 50,000 | D | ↗ |
| 2025-10-15 | Gerber Hans-Peter | Officer | P-Purchase | A | Common Stock | 17,000 | 0.80 | 13.6K | 71,832 | D | ↗ |
| 2025-10-15 | Chung Jane | Director / Officer | P-Purchase | A | Common Stock | 12,500 | 0.80 | 10.0K | 122,850 | D | ↗ |
| 2025-10-15 | Chow Gregory K. | Officer | P-Purchase | A | Common Stock | 19,750 | 0.81 | 16.0K | 19,750 | D | ↗ |
| 2025-09-18 | Gerber Hans-Peter | Officer | M-Exempt | A | Common Stock | 37,500 | 0.00 | — | 68,249 | D | ↗ |
| 2025-08-09 | Chung Jane | Director / Officer | M-Exempt | A | Common Stock | 18,750 | 0.00 | — | 117,058 | D | ↗ |
| 2025-07-08 | Leyman Barbara | Officer | M-Exempt | D | Restricted Stock Units (RSUs) | 25,000 | 0.00 | — | 75,000 | D | ↗ |
| 2025-06-06 | Wigginton Jon Marc | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.85 | 42.5K | 50,000 | D | ↗ |
| 2025-06-06 | Petree Daniel H | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.85 | 42.5K | 50,000 | D | ↗ |
| 2025-06-06 | PANEK JAMES P | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.85 | 42.5K | 50,000 | D | ↗ |
| 2025-06-06 | MATSUI CONNIE | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.85 | 42.5K | 50,000 | D | ↗ |
| 2025-06-06 | Lobacki Joseph M | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.85 | 42.5K | 50,000 | D | ↗ |
| 2025-06-06 | Jagpal Sukhi | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.85 | 42.5K | 50,000 | D | ↗ |
| 2025-06-06 | Hunter Heidi | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.85 | 42.5K | 50,000 | D | ↗ |
| 2025-06-06 | Dybbs Michael | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.85 | 42.5K | 50,000 | D | ↗ |
| 2025-06-02 | Chow Gregory K. | Officer | A-Award | A | Restricted Stock Unit (RSU) | 100,000 | 0.00 | — | 100,000 | D | ↗ |
| 2025-05-15 | ALBINI EDWARD C | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 9,125 | 0.00 | — | 0 | D | ↗ |
| 2025-05-01 | Srinivasan Venkatesh | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 2,500 | 0.00 | — | 5,000 | D | ↗ |
| 2025-05-01 | FITZPATRICK LINDA A | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 9,125 | 0.00 | — | 0 | D | ↗ |
| 2025-05-01 | Borgman Anne Elizabeth | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 15,938 | 0.00 | — | 17,812 | D | ↗ |
| 2025-04-11 | Srinivasan Venkatesh | Officer | M-Exempt | A | Common Stock | 21,250 | 0.00 | — | 59,683 | D | ↗ |
| 2025-04-04 | Srinivasan Venkatesh | Officer | A-Award | A | Stock Option (Right to Buy) | 101,500 | 0.55 | 55.8K | 101,500 | D | ↗ |
| 2025-04-04 | Pauling David | Officer | — | — | Stock Option (Right to Buy) | 23,000 | 6.55 | 150.7K | 0 | D | ↗ |
| 2025-04-04 | Leyman Barbara | Officer | A-Award | A | Restricted Stock Units (RSUs) | 84,500 | 0.00 | — | 84,500 | D | ↗ |
| 2025-04-04 | Gerber Hans-Peter | Officer | A-Award | A | Restricted Stock Units (RSUs) | 113,750 | 0.00 | — | 113,750 | D | ↗ |
| 2025-04-04 | Chung Jane | Director / Officer | A-Award | A | Restricted Stock Units (RSUs) | 310,000 | 0.00 | — | 310,000 | D | ↗ |
| 2025-03-05 | NEWELL WILLIAM J | Director / Officer | F-InKind | D | Common Stock | 6,708 | 1.36 | 9.1K | 292,531 | D | ↗ |
| 2025-03-05 | FITZPATRICK LINDA A | Officer | F-InKind | D | Common Stock | 3,594 | 1.36 | 4.9K | 95,433 | D | ↗ |
| 2025-03-05 | ALBINI EDWARD C | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 8,750 | 0.00 | — | 0 | D | ↗ |
| 2025-03-04 | NEWELL WILLIAM J | Director / Officer | F-InKind | D | Common Stock | 11,136 | 1.42 | 15.8K | 280,489 | D | ↗ |
| 2025-03-04 | FITZPATRICK LINDA A | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 9,125 | 0.00 | — | 9,125 | D | ↗ |
| 2025-03-04 | Chung Jane | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 7,875 | 0.00 | — | 7,875 | D | ↗ |
| 2025-03-01 | Srinivasan Venkatesh | Officer | M-Exempt | A | Common Stock | 6,375 | 0.00 | — | 43,105 | D | ↗ |
| 2025-03-01 | NEWELL WILLIAM J | Director / Officer | M-Exempt | A | Common Stock | 41,750 | 0.00 | — | 285,703 | D | ↗ |
| 2025-03-01 | Gerber Hans-Peter | Officer | F-InKind | D | Common Stock | 4,621 | 1.59 | 7.3K | 30,749 | D | ↗ |
| 2025-03-01 | FITZPATRICK LINDA A | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 6,875 | 0.00 | — | 13,750 | D | ↗ |
| 2025-03-01 | Chung Jane | Officer | F-InKind | D | Common Stock | 9,450 | 1.59 | 15.0K | 92,767 | D | ↗ |
| 2025-03-01 | Borgman Anne Elizabeth | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 11,250 | 0.00 | — | 33,750 | D | ↗ |
| 2025-03-01 | ALBINI EDWARD C | Officer | F-InKind | D | Common Stock | 10,320 | 1.59 | 16.4K | 121,548 | D | ↗ |
| 2025-02-28 | Borgman Anne Elizabeth | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 37,500 | 0.00 | — | 75,000 | D | ↗ |
| 2024-12-01 | Chung Jane | Officer | F-InKind | D | Common Stock | 8,920 | 2.69 | 24.0K | 70,342 | D | ↗ |
| 2024-09-18 | Gerber Hans-Peter | Officer | M-Exempt | A | Common Stock | 37,500 | 0.00 | — | 37,500 | D | ↗ |
| 2024-08-09 | Chung Jane | Officer | M-Exempt | A | Common Stock | 18,750 | 0.00 | — | 60,951 | — | ↗ |
| 2024-08-08 | Jagpal Sukhi | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 3.22 | 112.7K | 35,000 | — | ↗ |
| 2024-07-08 | Leyman Barbara | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-06-06 | Wigginton Jon Marc | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 3.76 | 131.6K | 35,000 | — | ↗ |
| 2024-06-06 | Petree Daniel H | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 3.76 | 131.6K | 35,000 | — | ↗ |
| 2024-06-06 | PANEK JAMES P | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 3.76 | 131.6K | 35,000 | — | ↗ |
| 2024-06-06 | MATSUI CONNIE | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 3.76 | 131.6K | 35,000 | — | ↗ |
| 2024-06-06 | Lobacki Joseph M | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 3.76 | 131.6K | 35,000 | — | ↗ |
| 2024-06-06 | Hunter Heidi | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 3.76 | 131.6K | 35,000 | — | ↗ |
| 2024-06-06 | Freund John Gordon | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 3.76 | 131.6K | 35,000 | — | ↗ |
| 2024-06-06 | Dybbs Michael | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 3.76 | 131.6K | 35,000 | — | ↗ |
| 2024-05-01 | Srinivasan Venkatesh | Officer | F-InKind | D | Common Stock | 892 | 3.74 | 3.3K | 31,730 | — | ↗ |
| 2024-04-11 | Srinivasan Venkatesh | Officer | M-Exempt | A | Common Stock | 21,250 | 0.00 | — | 37,704 | — | ↗ |
| 2024-03-07 | FITZPATRICK LINDA A | Officer | A-Award | A | Restricted Stock Units (RSUs) | 16,500 | 0.00 | — | 16,500 | — | ↗ |
| 2024-03-05 | Srinivasan Venkatesh | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 34,000 | 4.54 | 154.4K | 34,000 | — | ↗ |
| 2024-03-05 | NEWELL WILLIAM J | Director / Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 18,750 | 0.00 | — | 18,750 | — | ↗ |
| 2024-03-05 | Gerber Hans-Peter | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 60,000 | 4.54 | 272.4K | 60,000 | — | ↗ |
| 2024-03-05 | FITZPATRICK LINDA A | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 38,000 | 4.54 | 172.5K | 38,000 | — | ↗ |
| 2024-03-05 | Chung Jane | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 50,000 | 4.54 | 227.0K | 50,000 | — | ↗ |
| 2024-03-05 | Borgman Anne Elizabeth | Officer | A-Award | A | Restricted Stock Units (RSUs) | 45,000 | 0.00 | — | 45,000 | — | ↗ |
| 2024-03-05 | ALBINI EDWARD C | Officer | M-Exempt | A | Common Stock | 8,750 | 0.00 | — | 109,843 | — | ↗ |
| 2024-03-04 | NEWELL WILLIAM J | Director / Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 31,125 | 0.00 | — | 62,250 | — | ↗ |
| 2024-03-04 | FITZPATRICK LINDA A | Officer | M-Exempt | A | Common Stock | 9,125 | 0.00 | — | 71,049 | — | ↗ |
| 2024-03-04 | Chung Jane | Officer | M-Exempt | A | Common Stock | 7,875 | 0.00 | — | 44,410 | — | ↗ |
| 2024-03-04 | ALBINI EDWARD C | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 9,125 | 0.00 | — | 18,250 | — | ↗ |
| 2024-03-01 | Srinivasan Venkatesh | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 5,000 | 0.00 | — | 15,000 | — | ↗ |
| 2024-03-01 | NEWELL WILLIAM J | Director / Officer | F-InKind | D | Common Stock | 8,559 | 4.95 | 42.4K | 188,123 | — | ↗ |
| 2024-03-01 | FITZPATRICK LINDA A | Officer | F-InKind | D | Common Stock | 2,511 | 4.95 | 12.4K | 61,924 | — | ↗ |
| 2024-03-01 | Chung Jane | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 6,875 | 0.00 | — | 20,625 | — | ↗ |
| 2024-03-01 | ALBINI EDWARD C | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 7,875 | 0.00 | — | 23,625 | — | ↗ |
| 2024-02-29 | Borgman Anne Elizabeth | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 37,500 | 0.00 | — | 112,500 | — | ↗ |
| 2024-01-29 | Vasquez Nicki | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 2,500 | 0.00 | — | 0 | — | ↗ |
| 2024-01-29 | NEWELL WILLIAM J | Director / Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 13,750 | 0.00 | — | 0 | — | ↗ |
| 2024-01-29 | FITZPATRICK LINDA A | Officer | M-Exempt | A | Common Stock | 8,250 | 0.00 | — | 60,940 | — | ↗ |
| 2024-01-29 | ALBINI EDWARD C | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 5,250 | 0.00 | — | 0 | — | ↗ |
| 2023-12-01 | Chung Jane | Officer | A-Award | A | Restricted Stock Unit (RSU) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2023-09-18 | Gerber Hans-Peter | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-28 | Shtylla Brunilda | Officer | S-Sale | D | Common Stock | 15,428 | 4.71 | 72.6K | 0 | — | ↗ |
| 2023-08-25 | Shtylla Brunilda | Officer | S-Sale | D | Common Stock | 11,613 | 4.59 | 53.3K | 12,928 | — | ↗ |
| 2023-08-09 | Chung Jane | Officer | M-Exempt | A | Common Stock | 18,750 | 0.00 | — | 38,181 | — | ↗ |
| 2023-07-12 | Vasquez Nicki | Officer | M-Exempt | A | Common Stock | 3,250 | 0.00 | — | 26,111 | — | ↗ |
| 2023-06-27 | Petree Daniel H | Director | G-Gift | D | Common Stock | 18,409 | 0.00 | — | 3,856 | — | ↗ |
| 2023-06-08 | Wigginton Jon Marc | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 5.12 | 128.0K | 25,000 | — | ↗ |
| 2023-06-08 | Petree Daniel H | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 5.12 | 128.0K | 25,000 | — | ↗ |
| 2023-06-08 | PANEK JAMES P | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 5.12 | 128.0K | 25,000 | — | ↗ |
| 2023-06-08 | MATSUI CONNIE | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 5.12 | 128.0K | 25,000 | — | ↗ |
| 2023-06-08 | Lobacki Joseph M | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 5.12 | 128.0K | 25,000 | — | ↗ |
| 2023-06-08 | Hunter Heidi | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 5.12 | 128.0K | 25,000 | — | ↗ |
| 2023-06-08 | Freund John Gordon | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 5.12 | 128.0K | 25,000 | — | ↗ |
| 2023-06-08 | Dybbs Michael | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 5.12 | 128.0K | 25,000 | — | ↗ |
| 2023-05-01 | Srinivasan Venkatesh | Officer | — | D | Stock Option (right to buy) | 150,000 | 6.77 | 1.02M | 0 | — | ↗ |
| 2023-04-14 | Hallam Trevor | Officer | M-Exempt | A | Common Stock | 3,750 | 0.00 | — | 101,664 | — | ↗ |
| 2023-03-15 | Borgman Anne Elizabeth | Officer | A-Award | A | Stock Option (right to buy Common Stock) | 175,000 | 5.40 | 945.0K | 175,000 | — | ↗ |
| 2023-03-03 | Vasquez Nicki | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 6,750 | 0.00 | — | 20,250 | — | ↗ |
| 2023-03-03 | Shtylla Brunilda | Officer | A-Award | A | Stock Option (right to buy Common Stock) | 40,000 | 5.79 | 231.6K | 40,000 | — | ↗ |
| 2023-03-03 | Shabbir Anik | Officer | M-Exempt | A | Common Stock | 8,750 | 0.00 | — | 47,049 | — | ↗ |
| 2023-03-03 | NEWELL WILLIAM J | Director / Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 31,125 | 0.00 | — | 93,375 | — | ↗ |
| 2023-03-03 | Hallam Trevor | Officer | A-Award | A | Restricted Stock Unit (RSU) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2023-03-03 | FITZPATRICK LINDA A | Officer | M-Exempt | A | Common Stock | 8,750 | 0.00 | — | 59,085 | — | ↗ |
| 2023-03-03 | Chung Jane | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 7,875 | 0.00 | — | 23,625 | — | ↗ |
| 2023-03-03 | ALBINI EDWARD C | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 8,750 | 0.00 | — | 17,500 | — | ↗ |
| 2023-03-01 | Shtylla Brunilda | Officer | — | D | Common Stock | 0 | 0.00 | — | 17,952 | — | ↗ |
| 2023-02-28 | Borgman Anne Elizabeth | Officer | — | D | No securities beneficially held | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-02-13 | ALBINI EDWARD C | Officer | M-Exempt | D | Stock Option (right to buy) | 45,698 | 5.81 | 265.4K | 0 | — | ↗ |
| 2023-01-27 | Vasquez Nicki | Officer | M-Exempt | A | Common Stock | 2,500 | 0.00 | — | 16,620 | — | ↗ |
| 2023-01-27 | Shabbir Anik | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 4,500 | 0.00 | — | 4,500 | — | ↗ |
| 2023-01-27 | NEWELL WILLIAM J | Director / Officer | M-Exempt | A | Common Stock | 13,750 | 0.00 | — | 137,787 | — | ↗ |
| 2023-01-27 | Hallam Trevor | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 5,250 | 0.00 | — | 5,250 | — | ↗ |
| 2023-01-27 | FITZPATRICK LINDA A | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 8,250 | 0.00 | — | 8,250 | — | ↗ |
| 2023-01-27 | ALBINI EDWARD C | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 5,250 | 0.00 | — | 5,250 | — | ↗ |
| 2022-08-09 | Chung Jane | Officer | M-Exempt | A | Common Stock | 18,750 | 0.00 | — | 21,250 | — | ↗ |
| 2022-07-12 | Vasquez Nicki | Officer | M-Exempt | A | Common Stock | 3,250 | 0.00 | — | 15,243 | — | ↗ |
| 2022-06-06 | Wigginton Jon Marc | Director | A-Award | A | Stock Option (right to buy) | 18,500 | 0.00 | — | 18,500 | — | ↗ |
| 2022-06-06 | Sharp Shalini | Director | A-Award | A | Stock Option (right to buy) | 18,500 | 4.44 | 82.1K | 18,500 | — | ↗ |
| 2022-06-06 | Petree Daniel H | Director | A-Award | A | Stock Option (right to buy) | 18,500 | 0.00 | — | 18,500 | — | ↗ |
| 2022-06-06 | PANEK JAMES P | Director | A-Award | A | Stock Option (right to buy) | 18,500 | 0.00 | — | 18,500 | — | ↗ |
| 2022-06-06 | MATSUI CONNIE | Director | A-Award | A | Stock Option (right to buy) | 18,500 | 4.44 | 82.1K | 18,500 | — | ↗ |
| 2022-06-06 | Lobacki Joseph M | Director | A-Award | A | Stock Option (right to buy) | 18,500 | 0.00 | — | 18,500 | — | ↗ |
| 2022-06-06 | Hunter Heidi | Director | A-Award | A | Stock Option (right to buy) | 18,500 | 0.00 | — | 18,500 | — | ↗ |
| 2022-06-06 | Freund John Gordon | Director | A-Award | A | Stock Option (right to buy) | 18,500 | 0.00 | — | 18,500 | — | ↗ |
| 2022-06-06 | Dybbs Michael | Director | A-Award | A | Stock Option (right to buy) | 18,500 | 0.00 | — | 18,500 | — | ↗ |
| 2022-04-14 | Hallam Trevor | Officer | M-Exempt | A | Common Stock | 3,750 | 0.00 | — | 81,567 | — | ↗ |
| 2022-03-14 | NEWELL WILLIAM J | Officer | P-Purchase | A | Common Stock | 10,000 | 7.75 | 77.5K | 116,525 | — | ↗ |
| 2022-03-05 | NEWELL WILLIAM J | Director / Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 18,750 | 0.00 | — | 56,250 | — | ↗ |
| 2022-03-05 | MOLINA ARTURO MD | Officer | M-Exempt | A | Common Stock | 12,500 | 0.00 | — | 42,091 | — | ↗ |
| 2022-03-05 | Hallam Trevor | Officer | M-Exempt | A | Common Stock | 12,500 | 0.00 | — | 82,095 | — | ↗ |
| 2022-03-04 | Vasquez Nicki | Officer | F-InKind | D | Common Stock | 2,253 | 8.17 | 18.4K | 11,993 | — | ↗ |
| 2022-03-04 | Shabbir Anik | Officer | A-Award | A | Stock Option (right to buy Common Stock) | 42,000 | 0.00 | — | 42,000 | — | ↗ |
| 2022-03-04 | NEWELL WILLIAM J | Director / Officer | A-Award | A | Stock Option (right to buy Common Stock) | 166,000 | 8.17 | 1.36M | 166,000 | — | ↗ |
| 2022-03-04 | MOLINA ARTURO MD | Officer | A-Award | A | Restricted Stock Unit (RSU) | 39,000 | 0.00 | — | 39,000 | — | ↗ |
| 2022-03-04 | Hallam Trevor | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 12,500 | 0.00 | — | 37,500 | — | ↗ |
| 2022-03-04 | FITZPATRICK LINDA A | Officer | M-Exempt | A | Common Stock | 8,750 | 0.00 | — | 39,296 | — | ↗ |
| 2022-03-04 | Chung Jane | Officer | A-Award | A | Restricted Stock Unit (RSU) | 31,500 | 0.00 | — | 31,500 | — | ↗ |
| 2022-03-04 | ALBINI EDWARD C | Officer | A-Award | A | Stock Option (right to buy Common Stock) | 42,000 | 0.00 | — | 42,000 | — | ↗ |
| 2022-02-08 | Petree Daniel H | Director | M-Exempt | A | Common Stock | 3,540 | 5.81 | 20.6K | 22,265 | — | ↗ |
| 2022-01-29 | Vasquez Nicki | Officer | M-Exempt | A | Common Stock | 2,500 | 0.00 | — | 9,770 | — | ↗ |
| 2022-01-29 | Shabbir Anik | Officer | F-InKind | D | Common Stock | 1,844 | 10.39 | 19.2K | 22,209 | — | ↗ |
| 2022-01-29 | NEWELL WILLIAM J | Director / Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 13,750 | 0.00 | — | 27,500 | — | ↗ |
| 2022-01-29 | MOLINA ARTURO MD | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 5,250 | 0.00 | — | 10,500 | — | ↗ |
| 2022-01-29 | Hallam Trevor | Officer | M-Exempt | A | Common Stock | 5,250 | 0.00 | — | 71,746 | — | ↗ |
| 2022-01-29 | FITZPATRICK LINDA A | Officer | F-InKind | D | Common Stock | 3,380 | 10.39 | 35.1K | 30,546 | — | ↗ |
| 2022-01-29 | ALBINI EDWARD C | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 5,250 | 0.00 | — | 10,500 | — | ↗ |
| 2021-12-30 | NEWELL WILLIAM J | Director / Officer | J-Other | A | Common Stock | 1,863 | 0.00 | — | 106,525 | — | ↗ |
| 2021-11-19 | Hunter Heidi | Director | A-Award | A | Stock Option (right to buy Common Stock) | 9,884 | 17.56 | 173.6K | 9,884 | — | ↗ |
| 2021-09-28 | Vasquez Nicki | Officer | S-Sale | D | Common Stock | 3,906 | 18.62 | 72.7K | 7,270 | — | ↗ |
| 2021-09-24 | Vasquez Nicki | Officer | M-Exempt | A | Common Stock | 5,969 | 0.00 | — | 13,239 | — | ↗ |
| 2021-09-24 | Shabbir Anik | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 8,609 | 0.00 | — | 0 | — | ↗ |
| 2021-09-24 | NEWELL WILLIAM J | Director / Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 25,253 | 0.00 | — | 0 | — | ↗ |
| 2021-09-24 | MOLINA ARTURO MD | Officer | F-InKind | D | Common Stock | 2,976 | 19.23 | 57.2K | 26,492 | — | ↗ |
| 2021-09-24 | Hallam Trevor | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 11,019 | 0.00 | — | 0 | — | ↗ |
| 2021-09-24 | FITZPATRICK LINDA A | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 7,576 | 0.00 | — | 0 | — | ↗ |
| 2021-09-24 | ALBINI EDWARD C | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 7,174 | 0.00 | — | 0 | — | ↗ |
| 2021-08-09 | Vasquez Nicki | Officer | — | D | Stock Option (right to buy) | 107,438 | 15.00 | 1.61M | 0 | — | ↗ |
| 2021-08-09 | Chung Jane | Officer | A-Award | A | Stock Option (right to buy) | 160,000 | 18.37 | 2.94M | 160,000 | — | ↗ |
| 2021-07-01 | NEWELL WILLIAM J | Director / Officer | G-Gift | D | Common Stock | 104,662 | 0.00 | — | 80,687 | — | ↗ |
| 2021-06-03 | Wigginton Jon Marc | Director | A-Award | A | Stock Option (right to buy) | 18,500 | 18.21 | 336.9K | 18,500 | — | ↗ |
| 2021-06-03 | Sharp Shalini | Director | A-Award | A | Stock Option (right to buy) | 18,500 | 18.21 | 336.9K | 18,500 | — | ↗ |
| 2021-06-03 | Petree Daniel H | Director | A-Award | A | Stock Option (right to buy) | 18,500 | 18.21 | 336.9K | 18,500 | — | ↗ |
| 2021-06-03 | PANEK JAMES P | Director | A-Award | A | Stock Option (right to buy) | 18,500 | 18.21 | 336.9K | 18,500 | — | ↗ |
| 2021-06-03 | MATSUI CONNIE | Director | A-Award | A | Stock Option (right to buy) | 18,500 | 18.21 | 336.9K | 18,500 | — | ↗ |
| 2021-06-03 | Lobacki Joseph M | Director | A-Award | A | Stock Option (right to buy) | 18,500 | 18.21 | 336.9K | 18,500 | — | ↗ |
| 2021-06-03 | Freund John Gordon | Director | A-Award | A | Stock Option (right to buy) | 18,500 | 18.21 | 336.9K | 18,500 | — | ↗ |
| 2021-06-03 | Dybbs Michael | Director | A-Award | A | Stock Option (right to buy) | 18,500 | 18.21 | 336.9K | 18,500 | — | ↗ |
| 2021-04-16 | Hallam Trevor | Officer | A-Award | A | Stock Option (right to buy Common Stock) | 20,000 | 20.01 | 400.2K | 20,000 | — | ↗ |
| 2021-03-05 | Shabbir Anik | Officer | A-Award | A | Restricted Stock Unit (RSU) | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2021-03-05 | NEWELL WILLIAM J | Director / Officer | A-Award | A | Restricted Stock Unit (RSU) | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2021-03-05 | MOLINA ARTURO MD | Officer | A-Award | A | Restricted Stock Unit (RSU) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2021-03-05 | Hallam Trevor | Officer | A-Award | A | Restricted Stock Unit (RSU) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2021-03-05 | FITZPATRICK LINDA A | Officer | A-Award | A | Restricted Stock Unit (RSU) | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2021-03-05 | ALBINI EDWARD C | Officer | A-Award | A | Restricted Stock Unit (RSU) | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2021-01-29 | Shabbir Anik | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 4,500 | 0.00 | — | 9,000 | — | ↗ |
| 2021-01-29 | NEWELL WILLIAM J | Director / Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 13,750 | 0.00 | — | 41,250 | — | ↗ |
| 2021-01-29 | MOLINA ARTURO MD | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 5,250 | 0.00 | — | 15,750 | — | ↗ |
| 2021-01-29 | Hallam Trevor | Officer | M-Exempt | A | Common Stock | 5,250 | 0.00 | — | 61,367 | — | ↗ |
| 2021-01-29 | FITZPATRICK LINDA A | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 8,250 | 0.00 | — | 24,750 | — | ↗ |
| 2021-01-29 | ALBINI EDWARD C | Officer | F-InKind | D | Common Stock | 2,126 | 22.15 | 47.1K | 14,200 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-390.2K
Shares Outstanding
8.50M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | William J. Newell Former Chief Executive Officer | 239.7K | — | — | — | — | 1.43M | 1.67M | 0.00% | ↗ |
| 2 | 2025 | Jane Chung, R.Ph. Chief Executive Officer | 652.0K | — | 167.4K | 245.3K | 465.8K | 45.5K | 1.58M | 26.19% | ↗ |
| 3 | 2025 | Hans-Peter Gerber, Ph.D. Chief Scientific Officer | 527.5K | — | 61.4K | 110.1K | 243.8K | — | 942.9K | 18.19% | ↗ |
| 4 | 2025 | Gregory Chow Chief Financial Officer | 277.1K | 25.0K | 88.0K | 245.9K | 218.5K | — | 854.5K | 39.08% | ↗ |
| 5 | 2024 | William J. Newell Chief Executive Officer | 707.5K | — | 758.2K | 589.4K | 277.3K | — | 2.33M | 57.78% | ↗ |
| 6 | 2024 | William J. Newell Former Chief Executive Officer | 707.5K | — | 758.2K | 589.4K | 277.3K | — | 2.33M | 57.78% | ↗ |
| 7 | 2024 | Jane Chung, R.Ph. Chief Executive Officer | 560.0K | — | 454.0K | 169.4K | 182.0K | 78.0K | 1.44M | 43.19% | ↗ |
| 8 | 2024 | Jane Chung, R.Ph. President and Chief Operating Officer | 560.0K | — | 454.0K | 169.4K | 182.0K | 78.0K | 1.44M | 43.19% | ↗ |
| 9 | 2024 | Edward Albini Chief Financial Officer | 498.8K | — | 313.3K | 230.3K | 130.9K | — | 1.17M | 46.33% | ↗ |
| 10 | 2024 | Hans-Peter Gerber, Ph.D. Chief Scientific Officer | 512.5K | 100.0K | 204.3K | 203.2K | 133.9K | — | 1.15M | 35.32% | ↗ |
| 11 | 2023 | Anne Borgman, M.D. Chief Medical Officer | 419.0K | 250.0K | 810.0K | 676.6K | 180.0K | — | 2.34M | 63.65% | ↗ |
| 12 | 2023 | William J. Newell Chief Executive Officer | 686.7K | — | 550.1K | 520.7K | 372.6K | — | 2.13M | 50.27% | ↗ |
| 13 | 2023 | Hans-Peter Gerber Chief Scientific Officer | 145.8K | 250.0K | 565.5K | 485.6K | 180.0K | — | 1.63M | 64.61% | ↗ |
| 14 | 2023 | Jane Chung, R.Ph. President and Chief Operating Officer | 506.2K | — | 434.2K | 236.9K | 227.8K | 92.0K | 1.50M | 44.83% | ↗ |
| 15 | 2023 | Edward Albini Chief Financial Officer | 470.8K | — | 182.4K | 195.8K | 169.5K | — | 1.02M | 37.13% | ↗ |
| 16 | 2022 | Trevor Hallam, Ph.D. Chief Scientific Officer | 512.5K | — | 318.6K | 297.3K | 257.5K | 139.5K | 1.53M | 40.38% | ↗ |
| 17 | 2022 | Jane Chung, RPh Chief Commercial Officer | 486.9K | 150.0K | 257.4K | 240.1K | 195.7K | 102.0K | 1.43M | 34.74% | ↗ |
| 18 | 2021 | William J. Newell Chief Executive Officer | 625.0K | — | 1.58M | 2.99M | 393.8K | 37.7K | 5.63M | 81.25% | ↗ |
| 19 | 2021 | Jane Chung, RPh Chief Commercial Officer | 188.0K | 300.0K | 1.38M | 2.04M | 199.5K | 145.0K | 4.25M | 80.43% | ↗ |
| 20 | 2021 | Trevor Hallam, Ph.D. Chief Scientific Officer | 488.3K | — | 1.36M | 1.18M | 262.5K | 132.0K | 3.42M | 74.19% | ↗ |
| 21 | 2021 | Arturo Molina, M.D., M.S., FACP, Chief Medical Officer | 481.1K | — | 1.06M | 898.2K | 202.1K | 8.6K | 2.65M | 73.85% | ↗ |
| 22 | 2021 | Edward Albini Chief Financial Officer | 420.0K | — | 738.9K | 748.5K | 176.4K | — | 2.08M | 71.38% | ↗ |
| 23 | 2020 | William J. Newell Chief Executive Officer | 554.0K | — | 555.0K | 707.5K | 318.6K | 20.5K | 2.16M | 58.57% | ↗ |
| 24 | 2020 | Linda Fitzpatrick Chief People and Communications Officer | 381.9K | 25.0K | 333.0K | 375.0K | 175.7K | 13.2K | 1.30M | 54.30% | ↗ |
| 25 | 2020 | Trevor Hallam, Ph.D. Chief Scientific Officer | 430.5K | — | 211.9K | 268.9K | 198.0K | 132.0K | 1.24M | 38.73% | ↗ |
| 26 | 2020 | Arturo Molina, M.D., M.S., FACP, Chief Medical Officer | 467.1K | — | 211.9K | 268.9K | 214.9K | 12.0K | 1.17M | 40.92% | ↗ |
| 27 | 2019 | William J. Newell Chief Executive Officer | 496.5K | — | — | 3.10M | 223.4K | — | 3.82M | 81.14% | ↗ |
| 28 | 2019 | Trevor Hallam, Ph.D. Chief Scientific Officer | 418.0K | — | — | 330.6K | 150.5K | 132.0K | 1.03M | 32.06% | ↗ |
| 29 | 2019 | Arturo Molina, M.D., M.S., FACP, Chief Medical Officer | 453.5K | — | — | 330.6K | 163.3K | — | 947.4K | 34.90% | ↗ |
| 30 | 2019 | Arturo Molina, M.D., M.S., FACP Chief Medical Officer | 453.5K | — | — | 330.6K | 163.3K | — | 947.4K | 34.90% | ↗ |
| 31 | 2019 | Linda Fitzpatrick Chief People and Communications Officer | 370.8K | — | — | 208.8K | 133.5K | — | 713.1K | 29.28% | ↗ |
| 32 | 2018 | William J. Newell Chief Executive Officer | 482.0K | — | 1.14M | 6.76M | 301.3K | — | 8.68M | 90.98% | ↗ |
| 33 | 2018 | Trevor Hallam, Ph.D. Chief Scientific Officer | 405.8K | — | 702.5K | 2.95M | 202.9K | 132.0K | 4.40M | 83.15% | ↗ |
| 34 | 2018 | Arturo Molina, M.D., M.S., FACP Chief Medical Officer | 440.3K | — | 387.4K | 2.31M | 220.2K | — | 3.35M | 80.31% | ↗ |
| 35 | 2017 | William J. Newell Chief Executive Officer | 467.6K | — | — | — | 199.0K | 35.9K | 702.5K | 0.00% | ↗ |
| 36 | 2017 | Trevor Hallam, Ph.D. Chief Scientific Officer | 394.0K | — | — | — | 134.0K | 150.0K | 677.9K | 0.00% | ↗ |
| 37 | 2017 | Arturo Molina, M.D., M.S., FACP Chief Medical Officer | 427.5K | — | — | — | 145.3K | — | 572.8K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jane Chung | Chief Executive Officer & Director | 1M | female |
| Hans-Peter Gerber | Chief Scientific Officer | 771.4K | — |
| Edward C. Albini | Secretary | 629.7K | male |
| Gregory K. Chow | Chief Financial Officer | 520.6K | male |
| Kari E. Leetch | Senior VP and Head of People & Culture | — | female |
| David Pauling | Chief Administrative Officer & General Counsel | — | male |
| Regina Cheng | Vice President & Controller | — | female |
| Devendra Luhar | Senior Vice President of Technical Operations | — | male |
| James R. Swartz | Founder | — | — |
| Jonathan Fawcett DPHIL MBBS | Vice President of Clinical Development | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for STRO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
